BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20129191)

  • 1. Diagnostic challenges in acromegaly: a case-based review.
    Bonert V
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S23-30. PubMed ID: 20129191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current diagnosis of acromegaly.
    Cordero RA; Barkan AL
    Rev Endocr Metab Disord; 2008 Mar; 9(1):13-9. PubMed ID: 18236162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical markers of acromegaly: GH vs. IGF-I.
    Barkan AL
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S97-100. PubMed ID: 15135787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current diagnostic guidelines for biochemical diagnosis of acromegaly.
    Ferone D; Resmini E; Bocca L; Giusti M; Barreca A; Minuto F
    Minerva Endocrinol; 2004 Dec; 29(4):207-23. PubMed ID: 15765030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are there alternative tests for diagnosis of acromegaly?
    Popovic V
    J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic testing in the diagnosis and follow-up of patients with acromegaly.
    Wass JA
    J Endocrinol Invest; 2003; 26(7 Suppl):48-53. PubMed ID: 14604066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acromegaly].
    Morange I; Jaquet P
    Rev Prat; 1996 Jun; 46(12):1482-5. PubMed ID: 8881161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurements.
    Katsumata N
    Pediatr Endocrinol Rev; 2017 Mar; 14 Suppl 1(Suppl 1):209-215. PubMed ID: 28516748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A follow-up of 130 patients with acromegaly in a single centre.
    Bolanowski M; Zatonska K; Kaluzny M; Zielinski G; Bednarek-Tupikowska G; Bohdanowicz-Pawlak A; Daroszewski J; Szymczak J; Podgorski JK
    Neuro Endocrinol Lett; 2006 Dec; 27(6):828-32. PubMed ID: 17187024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
    Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
    Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical laboratory indices in the treatment of acromegaly.
    Clemmons DR
    Clin Chim Acta; 2011 Feb; 412(5-6):403-9. PubMed ID: 21075098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.
    Pokrajac A; Wark G; Ellis AR; Wear J; Wieringa GE; Trainer PJ
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):65-70. PubMed ID: 17437512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical evidence supporting the Cortina criteria.
    von Werder K
    J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults.
    Thissen JP; Ketelslegers JM; Maiter D
    Growth Regul; 1996 Dec; 6(4):222-9. PubMed ID: 8971551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary tumours: acromegaly.
    Chanson P; Salenave S; Kamenicky P; Cazabat L; Young J
    Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):555-74. PubMed ID: 19945023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.